$GEGR The Company has agreed to terminate 100% of its
$GEGR The Company has agreed to terminate 100% of its interest Re-You Suisse SA. The termination of these two interests was requested due to financial issues relating to US based ownership of Switzerland based companies. The Company, in consideration of these actions, has been authorized and empowered to establish Stem Cells Biotech in the United States which will have the exclusive rights in North and South America, including Canada. The Company, in consideration of these actions, has been authorized and empowered to establish Re-You SA the United States which will have the exclusive rights in North and South America, including Canada. The company will retain 50% of the ownership of the two United States including the technological and intellectual property.
The Company will be providing additional updates the week of March 7th , including our filing of our Annual Report and information on new corporate transactions.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
SmartFinancial Announces Upcoming Earnings Release SmartFinancial, Inc. (NYSE: SMBK) has revealed important details regarding its Fourth Quarter earnings for the year 2024. This is an exciting time for investors and stakeholders as the company prepares to share insights into its financial performance. Earnings Release Date and Conference Call Information The earnings...
Continue Reading
IntouchCX Strengthens Trust and Safety Solutions Through Acquisition IntouchCX has recently made headlines with its acquisition of WebPurify, a leading provider of innovative content moderation solutions that harness the power of artificial intelligence. This strategic move represents a significant advancement in IntouchCX's mission to redefine Trust and Safety solutions,...
Continue Reading
Y-mAbs Therapeutics Engages Investors at Upcoming Conferences This September, Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB), a key player in the biopharmaceutical industry, is poised to attract investor interest. The company is known for its innovative radioimmunotherapy and antibody-based treatments designed to transform cancer care. Michael Rossi, the energetic CEO of...
Continue Reading
Overview of CorVel's Financial Performance CorVel Corporation (NASDAQ: CRVL) recently unveiled impressive results for the quarter and fiscal year, showcasing strong revenue gains and enhanced earnings metrics. The quarterly revenue hit $232 million, a notable rise from $207 million compared to the same quarter last year. This upward trend is mirrored across the fiscal...
Continue Reading
IQAX eBL Interoperability Approval Highlights IQAX Limited has made significant strides in enhancing its electronic bill of lading (eBL) solution by receiving official approval from the International Group of P&I Clubs (IG P&I Clubs). This approval affirms the capabilities of IQAX eBL's interoperable addendum, empowering users to perform eBL transactions across different...
Continue Reading
